Biotech Specialty Pharma

CytRx

11726 San Vicente Blvd., Suite 650
Los Angeles, CA 90049 USA
Phone
Fax
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Biopharmaceutical research and development company engaged in the development of human therapeutics.

Management Steven A. Kriegsman, President and Chief Executive Officer; Daniel Levitt, M.D., Ph.D., Chief Medical Officer; John Y. Caloz, Chief Financial Officer; Jaisim Shah, Senior Business Officer and Senior Vice President of Business Development; Benjamin S. Levin, General Counsel, Vice President of Legal Affairs and Corporate Secretary

Click here for Financial Data
Keywords: tamibarotene, bafetinib, arimoclomol, iroxanadine, proteins, RNAi, cancer,

Comment


Updated: May 26, 2018


Description

CytRx is a biopharmaceutical research and development company engaged in the development of human therapeutics.......view more

Products / Services

CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The CytRx drug development pipeline includes tamibarotene which i......view more

Technology / Differentiation

CytRx has several proprietary anti-cancer drug candidates in development. INNO-206 incorporates a unique acid-sensitive linker technology that allows for improved targeting to the tumor. This result...view more

Market / Customers

CytRx is developing drugs for various forms of cancer. Tamibarotene and bafetinib are being developed to treat different types of leukemias. INNO-206 has a linker technology for the treatment of sol......view more


Competitors / Substitutes / Alternatives

Celgene Corporation, Cephalon, Sanofi-Aventis...view more

Status

CytRxs lead compound Tamibarotene is in a pivotal phase 2 clinical trial with a Special Protocol Assessment with the FDA. The trial targets 3rd line APL. A phase 1/2 clinical trial with Tamibaroten...view more

RELATED COMPANIES